PMID- 7515984
OWN - NLM
STAT- MEDLINE
DCOM- 19940711
LR  - 20071115
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 23
IP  - 3
DP  - 1994 Mar
TI  - Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with 
      normal and decreased left ventricular function.
PG  - 408-14
AB  - The hemodynamic and pharmacokinetic effects of the novel class 1c antiarrhythmic 
      drug restacorin were investigated in two groups of patients. Group I consisted of 
      5 patients with normal left ventricular (LV) function, and group II consisted of 
      10 patients with mild heart failure [New York Heart Association (NYHA) II; mean 
      LV ejection fraction 33 +/- 6%]. The study had an open label, 
      baseline-controlled, single-dose design. Restacorin was infused in a total dosage 
      of 1.2 mg/kg. In group I, the only significant change as compared with baseline 
      findings was a 25% increase in right atrial pressure. In group II; cardiac output 
      (CO), dP/dt, and stroke work index (SWI) decreased significantly (-18, -11, and 
      -24%, respectively). In addition, a significant 32% increase was noted in 
      pulmonary artery wedge pressure (PAWP), and a 27% increase occurred in systemic 
      vascular resistance (SVR). No changes were observed in heart rate (HR) or mean 
      arterial blood pressure (MAP). CO and SVR at baseline correlated with the average 
      plasma concentrations (r = -0.65 and p = 0.009 and r = 0.56 and p = 0.028 
      respectively). Creatinine clearance was inversely correlated to the restacorin 
      plasma concentration (r = -0.51, p = 0.05). The half-life (t1/2) elimination time 
      of restacorin was 2.60 h for group I, and 4.06 h for group II. Clearance was 51.4 
      and 32.2 L.h-1, respectively. Restacorin appears to be well tolerated in patients 
      with normal LV function. The drug is not recommended for use in patients with 
      reduced LV function because of its moderate negative inotropic effect.
FAU - Tuininga, Y S
AU  - Tuininga YS
AD  - Department of Cardiology, University Hospital, Groningen, The Netherlands.
FAU - Crijns, H J
AU  - Crijns HJ
FAU - Oosterhuis, B
AU  - Oosterhuis B
FAU - Wiesfeld, A C
AU  - Wiesfeld AC
FAU - van Wijk, L M
AU  - van Wijk LM
FAU - Albronda, F
AU  - Albronda F
FAU - de Bruin, H
AU  - de Bruin H
FAU - Jonkman, J H
AU  - Jonkman JH
FAU - Kozma, C
AU  - Kozma C
FAU - Lie, K I
AU  - Lie KI
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Guanidines)
RN  - 100751-82-4 (restacorin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Arrhythmia Agents/adverse effects/pharmacokinetics/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Cardiac Output/drug effects
MH  - Female
MH  - Guanidines/adverse effects/pharmacokinetics/*pharmacology
MH  - Half-Life
MH  - Heart Failure/physiopathology
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Wedge Pressure/drug effects
MH  - Vascular Resistance/drug effects
MH  - Ventricular Function, Left/*drug effects
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1994 Mar;23(3):408-14.